On Invalid Date, Cerevel Therapeutics Holdings (NASDAQ: CERE) reported Q3 2023 earnings per share (EPS) of -$0.61, up 7.58% year over year. Total Cerevel Therapeutics Holdings earnings for the quarter were -$96.36 million. In the same quarter last year, Cerevel Therapeutics Holdings's earnings per share (EPS) was -$0.66.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.